Most Read

Researchers at Camino Pharma, Sanford Burnham Prebys and the University of California San Diego School of Medicine received the three-year grant. The funds will facilitate longer toxicology studies

Under the deal terms, Bluejay will have the sole licence to Exicure’s patents relevant to hepatitis. Bluejay made an initial payment to Exicure following the deal execution. In

The transaction, which was executed through Zuellig Pharma’s wholly-owned subsidiary Zanovex, encompasses several Association of Southeast Asian Nations (ASEAN) territories. These markets include Cambodia, Brunei, Laos, Indonesia, Malaysia,

This designation could lead to seven years of marketing exclusivity on receipt of an approval, as well as exemption from user fees and eligibility for tax credits. Furthermore,

Tyruko is indicated as a single disease-modifying therapy (DMT) for adults diagnosed with highly active RRMS.  This is the same indication that was approved by the European Commission

Pancreatic cancer is known for its poor prognosis and high mortality rate. With a combined annual death toll of 139,000 in the US and European Union, it is

The approval allows Oricell to commence clinical development of OriCAR-017 in the US, with immediate effect. Utilising Oricell’s platforms, including OriAb antibodies, OriCAR construct, and unique CMC know-how,

The treatment is intended for usage in adults with priorly untreated la/mUC. This development marks a significant step towards potentially offering an alternative to the current standard platinum-containing

The facility is designed to bolster in-house production of drug substances for Investigational New Drug (IND)-enabling studies and trials. This development is pivotal for the company’s proprietary and